Novo Nordisk A/s

Transtech Pharma, Inc.

Sanofi

Zoetis Services LLC

Vtv Therapeutics LLC

Govindan Subramanian

Robert Carl Andrews

Jesper F Lau

Dharma Rao Polisetti

Lone Jeppesen

Anthony Murray

Michael Ankersen

Adnan M M Mjalli

Kalpathy Chidambareswaran Santhosh

Daniel Peter Christen

Per Vedsø

Mustafa Guzel

Janos Tibor Kodra

Jane Marie Lundbeck

Marit Kristiansen

Per Vedso

Paw Bloch

Jeremy T Cooper

Maria Carmen Valcarce-Lopez

Richard Andrew Ewin

Jeff Jiqun Zhu

Nicolas Baurin

Han Li

Matthew Davison

Dorothea Kominos

Murty N Arimilli

Alla Pritsker

Xin Chen

Jie Zhang

James C Quada, Jr

Stephen Thomas Davis

Ramesh Gopalaswamy

Rongyuan Xie

Ravindra Reddy Yarragunta

János Tibor Kodra

Brian S Grella

Xiaochuan Guo

Niels Blume

Jinxia (Nancy) Deng

Maria Carmen Valcarce Lopez

Bapu Reddy Gaddam

Michael P Curtis

Samuel F Victory

Graham M Kyne

Ghassan Qabaja

Tomasz Respondek

Ye Edward Tian

John Adam Wendt

Susan Mary Kult Sheehan

Adnan Mm Mjalli

Per Vedsoe

Christopher Scott Knauer

Jinxia Deng

John Dankwardt

Santhosh Chidambareswaran Kalpathy

Ashley E Fenwick

James C Quada

Daniel P Christen

Andrew Ewin Richard

James C Quada,

Jinxia (nancy) Deng

Adnan MM Mjalli

The compounds of the invention, as described herein, are novel serotonin 5-HT2B antagonists useful for the treatment of myxomatous mitral valve degeneration (MMVD), congestive heart failure (CHF), and/or asymptomatic heart failure in animals, preferably canine.

Serotonin 5-HT2B inhibitory compounds

The invention describes novel serotonin c5-HT2B receptor antagonists of Formula (1), and pharmaceutically acceptable salts thereof; wherein Ring A, L, X, X′, R, R, m and n are as defined herein. Also described are compositions comprising a Formula (1) compound, or a pharmaceutically acceptable salt thereof; and methods of using the compounds, or a pharmaceutically acceptable salt thereof, for the treatment of myxomatous mitral valve disease (MMVD), congestive heart failure (CHF) and/or asymptomatic heart failure in animals, preferably is a canine.

The present invention provides Formula (1) compounds that are gamma-carbolines, Formula (1) wherein R1, R1, R1, R1, R2, R3, and '-' are as defined herein; veterinary acceptable salts thereof, and stereoisomers thereof, which act as parasiticides, in particular, endoparasiticides.

Carboline antiparasitics

The invention provides antibodies that specifically bind to Kallidin or des-Arg10-Kallidin. The invention also provides pharmaceutical compositions, as well as nucleic acids encoding anti-Kallidin or des-Arg10-Kallidin antibodies, recombinant expression vectors and host cells for making such antibodies, or fragments thereof. Methods of using antibodies of the invention to modulate Kallidin or des-Arg10-Kallidin activity or detect Kallidin or des-Arg10-Kallidin or, either in vitro or in vivo, are also provided by the invention. The invention further provides methods of making antibodies that specifically bind to des-Arg-Bradykinin and des-Arg-Kallidin-like peptide.

Nucleic acids encoding antibodies to Kallidin and des-Arg-Kallidin and host cells comprising the same

[object Object]

This invention relates to aryl carbonyl derivatives which are activators of glucokinase which may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.

Aryl carbonyl derivatives as therapeutic agents

This invention relates to compounds of formula (I) which are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial.

Heteroaryl-ureas and their use as glucokinase activators

The present invention provides imidazole derivatives of Formula (I-IV), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I-IV), and their use in treating human or animal disorders. The compounds of the invention inhibit protein tyrosine phosphatase 1B and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.

Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors

The present invention relates to compounds and methods from the treatment of cancer. The invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising compounds that inhibit Aurora kinase, and methods for the treatment of cancer using the compounds of the presentation invention or pharmaceutical compositions comprising compounds of the present invention.

Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors

This invention relates to compounds that are activators of glucokinase and thus may be useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial. The compounds are of the general formula (I) wherein A and B are further defined in the application.

N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes

Growing community of inventors

High Point, NC, United States of America

Govindan Subramanian